Atomo Diagnostics (ASX:AT1) share price sinks 8% on FY21 results

Investors have been selling this medical device company's shares on Friday…

| More on:
A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Atomo Diagnostics Ltd (ASX: AT1) share price has been out of form on Friday.

Earlier today, the medical device company's shares fell as much as 8% to 22.5 cents. This was in response to the release of its full year results.

Atomo Diagnostics share price falls after losses double in FY 2021

  • Revenue increased 25% to $6.72 million
  • Cost of sales up 52% to $3.3 million
  • Gross profit up 7% to $3.42 million
  • Underlying operating loss widened 101% to $4.79 million
  • Cash balance of ~$18 million

What happened for Atomo in FY 2021?

For the 12 months ended 30 June, Atomo reported a 25.1% increase in revenue to $6.72 million.

This was driven largely by demand for devices from customers in Europe and North America for the production of COVID-19 antibody tests.

Also supporting its sales growth was demand in Australia for Atomo branded COVID-19 rapid antibody and antigen tests and its HIV products in Australia and internationally.

What did management say?

Management was pleased with the company's performance during a year filled with both headwinds and tailwinds.

It commented: "Atomo's activities continued throughout FY21 nothwithstanding the COVID-19 pandemic. There were some delays in activity caused by the pandemic, for example, the global tender for HIV Self Tests run by Unitaid was substantially delayed, the consequence of which was that Atomo's revenue from that tender was modest and primarily occured at the very end of the financial year."

"That said, a significant portion of additional revenue was driven by demand for Atomo's COVID-19 products in Australia and for its platforms for use by OEM customers in their own COVID-19 rapid tests internationally," it added.

What's next?

No guidance was given for the year ahead, which could be weighing on the Atomo share price a touch today.

However, management has stated that it is prioritising the continued expansion of strategic commercialisation partnerships across key global markets. This includes seeking a US market entry partnership.

In addition, it is aiming to expand its COVID-19 revenues with a core focus on the Australian market. It will also target HIV sales growth in existing territories and look to secure commercial agreements in new territories.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Earnings Results

Man jumps for joy in front of a background of a rising stocks graphic.
Earnings Results

Catapult shines: 20% sales growth propels ASX tech stock to new 52-week high

A strong annual result from this tech player has caught investor attention.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Earnings Results

Xero share price leaps 8% on staggering earnings upheaval

A major turnaround in profitability is sending investors into a frenzy over Xero shares today.

Read more »

a construction worker sits pensively at his desk with his arm propping up his chin as he looks at his laptop computer while wearing a hard hat and visibility vest in a bunker style construction shed.
Materials Shares

Which ASX 200 stock just plunged 12% despite record full-year earnings?

It looks like an impressive report card but UBS doesn't like the FY25 guidance.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Earnings Results

ASX 200 tech stock lifts off on another record-setting half-year profit

Investors are bidding up the ASX 200 tech company following its half-year results.

Read more »

increasing rural asx share price represented by happy looking sheep
Earnings Results

Why is this ASX All Ords stock staying strong as profits crash 76%

How is this company's share price marching higher after mowing down more than three-quarters of its profits compared to a…

Read more »

Two men sit side by side on a couch with video game controls in their hands and expressive looks on their faces as they react to the action in front of them in a home setting.
Earnings Results

Guess which ASX 200 stock is surging 11% on an 'outstanding' result

This ASX gaming giant just posted a 17% jump in profits, and its shareholders are basking in the glory.

Read more »

Agricultural ASX share price on watch represented by farmer in field looking at tablet computer.
Earnings Results

Graincorp share price lifts off as dividend is maintained and debts plunge

ASX 200 investors are bidding up the Graincorp share price today. But why?

Read more »

Smiling elderly couple looking at their superannuation account, symbolising retirement.
Earnings Results

Why is this ASX 200 stock avoiding the market selloff and pushing higher?

Not all shares are falling with the market on Thursday.

Read more »